1050 ET - Novo Nordisk's headline phase 1 results for amycretin are highly encouraging, Deutsche Bank analyst Emmanuel Papadakis writes. Amycretin is potentially instrumental to the investment case, and thus the results are a clear minor positive, he adds. Deutsche Bank continues to believe the disappointment over CagriSema's initial headline results is overdone, and hence the subsequent derating is a clear buying opportunity. The bank rates Novo Nordisk at buy with a 900 Danish kroner target price. Shares trade 1.8% lower following Friday's strong rally on the news. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
January 27, 2025 10:50 ET (15:50 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。